Innovative Solutions for Biotechnology Challenges
Designing cancer therapeutics that empower patients.
Targeted Therapy
At Geneovese we are developing novel therapeutics for pre-metastatic cancers with administration prior to radical interventions and which are suitable for palliative care.
As cancer becomes easier to detect in earlier stages, prevention and non-radical treatment options are needed as an option of care in oncology, and efficacious palliative care options without deleterious side effects are needed.
Our novel therapeutics are designed to empower patients with an option of treatment prior to radical surgery, chemotherapy, and for palliative care and end-of-life planning.
Target Indications
We're evaluating oncology indications where current treatments and classical targeted therapies underperform, and where our platform has a clear mechanistic advantage.
Our technology focuses on the controlled release of cell-targeted therapeutics, unlocking better tolerability with improved efficacy. We aim to deliver the most efficacious solutions in the preventative and palliative care oncology space.
Janet Little
Founder and CEO
Geneovese, Inc. is a female-founded and female-led biotech company based in Redmond, Washington.
We believe small companies doing big work will usher in the next wave of innovative medicines.
Get in Touch
Geneovese, Inc
(Delaware C-Corp)
Janet Little
Redmond, WA 98033
Represented by COJK PLLC: Seattle Intellectual Property (IP) Law Firm
